<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01361139</url>
  </required_header>
  <id_info>
    <org_study_id>DOP09</org_study_id>
    <nct_id>NCT01361139</nct_id>
  </id_info>
  <brief_title>Diagnosis of Cardio-Pulmonary Pathology Using Transthoracic Parametric Doppler (TPD)</brief_title>
  <official_title>Detection and Characterization of Cardio-Pulmonary Patho-Physiological States and Diseases by Transthoracic Parametric Doppler (TPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Echosense Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clalit Health Services, Haifa and West Galilee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Echosense Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study that seeks to characterize data obtained from patients with a variety of lung&#xD;
      diseases using ultrasound signals obtained from the lung tissue. A standard ultrasound&#xD;
      instrument in the doppler mode (not the imaging mode used in examination of pregnant women&#xD;
      for instance) is placed on the chest wall and the unique software the investigators have&#xD;
      developed analyzes the signal reflected back from within the lung. On the basis of pilot&#xD;
      studies performed previously the investigators expect to receive different signals from&#xD;
      different diseases. The investigators seek to further characterize these signals to enable&#xD;
      accurate diagnosis of different lung diseases using our technology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnose specific pattern of the LDS signals as Power and Velocity in pulmonary diseases in comparison to controls.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <enrollment type="Actual">500</enrollment>
  <condition>Lung Disease, Chronic Obstructive</condition>
  <condition>Lung Disease, Interstitial</condition>
  <condition>Asthma</condition>
  <condition>Sarcoidosis</condition>
  <condition>Hypertension, Pulmonary</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred to a large hospital-affiliated community lung clinic.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
        Age 18 years or older Patients who are clinically suspected of having pulmonary, cardiac or&#xD;
        Cardio-pulmonary disease preferably any one or more of the conditions listed below:&#xD;
&#xD;
          -  Patients with CHF&#xD;
&#xD;
          -  Patients with pulmonary hypertension with documented right heart catheterization data&#xD;
&#xD;
          -  Patients with COPD in two subgroups:&#xD;
&#xD;
               -  Emphysema, (evidence of emphysema on High Resolution Computed Tomography, (HRCT)&#xD;
                  and airflow limitation of GOLD II severity who have had Carbon Monoxide Diffusing&#xD;
                  capacity, (DLCO) and Residual Volume(RV) measured, or patients without HRCT with&#xD;
                  measurements of lung volumes and diffusing capacity with Total Lung Capacity&#xD;
                  (TLC) ≥1.0 predicted, RV/TLC ≥0.4, DLCO ≤ 0.7 predicted.&#xD;
&#xD;
               -  Chronic Bronchitis (No evidence of Emphysema on HRCT and/or no evidence of&#xD;
                  air-trapping or reduced DLCO.)&#xD;
&#xD;
          -  Patients with asthma according to ATS/ERS definition,&#xD;
&#xD;
          -  Patients with interstitial lung disease (ILD) of any etiology including sarcoidosis&#xD;
             diagnosed by HRCT in sub groups as follows:&#xD;
&#xD;
               -  Mild ILD (TLC 0.71-0.79 predicted, DLCO ≥ 0.71 predicted)&#xD;
&#xD;
               -  Moderate and severe ILD (TLC ≤ 0.7 predicted, DLCO ≤ 0.7 predicted)&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Patients with sarcoidosis without evidence of parenchymal lung disease defined as&#xD;
             normal DLCO and/or HRCT.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Patients unable to cooperate.&#xD;
&#xD;
          -  Inability to assume a semi-reclining or supine position&#xD;
&#xD;
          -  Patients with severe chest wall deformity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Weiler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Echosense Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uzi Milman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clalit Health Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regional Pulmonary Clinic, Clalit Health Services</name>
      <address>
        <city>Haifa</city>
        <zip>3505331</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinic for Pulmonary Disease, Haifa and Western Galilee, Clalit Health Services</name>
      <address>
        <city>Haifa</city>
        <zip>35053</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>May 25, 2011</study_first_submitted>
  <study_first_submitted_qc>May 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2011</study_first_posted>
  <last_update_submitted>January 14, 2015</last_update_submitted>
  <last_update_submitted_qc>January 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic obstructive lung disease</keyword>
  <keyword>Interstitial lung disease</keyword>
  <keyword>Asthma</keyword>
  <keyword>Sarcoidosis</keyword>
  <keyword>Pulmonary hypertension</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Doppler</keyword>
  <keyword>Lung disease diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

